✦ LIBER ✦

Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278)

✍ Scribed by Valentina Guarneri; Antonio Frassoldati; Paolo Bruzzi; Roberto D'Amico; Maurizio Belfiglio; Annamaria Molino; Oscar Bertetto; Stefano Cascinu; Francesco Cognetti; Angelo Di Leo; Paolo Pronzato; Lucio Crinó; Biagio Agostara; PierFranco Conte

Book ID: 115075805
Publisher: CIG Media Group, LP.
Year: 2008
Tongue: English
Weight: 95 KB
Volume: 8
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2008.n.056

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

Subcutaneous versus intravenous administ

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

✍ Gustavo Ismael; Roberto Hegg; Susanne Muehlbauer; Dominik Heinzmann; Bert Lum; S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 245 KB